Table 2.

Comparison of variables between cases and control subjects at follow-up

Variables	Cases		Control subjects		P value
	n	Median (IQR)	n	Median (IQR)
Follow-up, months	44	41 (30–64.48)	49	32 (26–41)	.002
Age at follow-up, months	44	48.5 (36–84.25)	49	48 (33.5–71)	.551
Blood urea, mg/dla	44	24 (20.25–29.75)	49	25 (21.5–30)	.592
Serum creatinine, mg/dla	44	0.4 (0.33–0.5)	49	0.4 (0.3–0.4)	.078
Urine albumin, mg/dla	44	6.3 (3.47–10.52)	48	6.68 (3.69–9.92)	.994
Urine creatinine, mg/dla	44	55.1 (33.2–85.95)	48	56.7 (35.55–93.15)	.904
Serum cystatin, mg/dla	44	0.74 (0.68–0.83)	49	0.71 (0.65–0.8)	.15
Urine NGAL, mg/dla	43	6.3 (3.6–12.9)	48	3.95 (0.9–8.35)	.037
IL-18, pg/dla	43	29 (24.83–34.86)	48	19.02 (14.23–25.77)	<.001
L-FABP, ng/dla	43	7.99 (5.08–16.05)	48	7.62 (5.22–10.84)	.871
KIM-1, ng/dl a	41	0.27 (0.21–0.41)	48	0.20 (0.12–0.29)	.002
BTP, mg/la	44	0.68 (0.57–0.71)	49	0.64 (0.56–0.75)	.979
Albumin creatinine ratio	44	0.11 (0.08–0.15)	48	0.1 (0.07–0.14)	.458
eGFR Schwartz, ml/min/1.73 m2	44	108.41 (96.2–124.28)	49	119.77 (101.01–133.88)	.085
eGFR cystatin C, ml/min/1.73 m2	44	90.8 (83.8–100.2)	49	98.3 (88.8–105.5)	.082
Urine IL-18/urine creatinine	43	0.46 (0.27–1.07)	48	0.35 (0.21–0.78)	.079
Urine L-FABP/urine creatinine	43	0.15 (0.0–0.46)	48	0.15 (0.09–0.32)	.697
Urine KIM-1/urine creatinine	41	0.005 (0.003–0.011)	48	0.003 (0.002–0.006)	.023
Urine NGAL/urine creatinine	43	0.12 (0.07–0.19)	48	0.08 (0.02–0.19)	.120

BTP, beta-trace protein; eGFR, estimated glomerular filtration rate; IL-18, interleukin-18; IQR, interquartile range; KIM-1, kidney injury molecule-1; L-FABP, liver-type fatty acid binding protein; NGAL, neutrophil gelatinase-associated lipocalin.

^aLast follow-up visit.